Name: | Enalapril |
---|---|
PubChem Compound ID: | 5362032 |
Description: | One of the ANGIOTENSIN-CONVERTING ENZYME INHIBITORS that is used to treat hypertension. |
Molecular formula: | C20H28N2O5 |
Molecular weight: | 376.447 g/mol |
Synonyms: |
Bonuten; L-Proline, 1-(N-(1-(ethoxycarbonyl)-3-phenylpropyl)-L-alanyl)-, (S)-; 172964-46-4; 1-(N-((S)-1-Carboxy-3-phenylpropyl)-L-alanyl)-L-proline 1'-ethyl ester; Enalapril Richet; Gadopril; Kinfil; Enalaprila [INN-Spanish]; L-Proline, N-((1S)-1-(ethoxycarbonyl)-3-phenylpropyl)-L-alanyl-; 75847-73-3.
show more » |
Name: | Enalapril |
---|---|
Name (isomeric): | DB00584 |
Drug Type: | small molecule |
Description: | One of the ANGIOTENSIN-CONVERTING ENZYME INHIBITORS that is used to treat hypertension. |
Synonyms: |
Enalaprila [INN-Spanish]; Enalaprilat; Enalapril Maleate; Enalaprilum [INN-Latin]
|
Brand: | Vasotec IV, Vasotec, Gadopril, Bonuten, Kinfil |
Brand name mixture: | Vaseretic(enalapril maleate + hydrochlorothiazide), Lexxel(enalapril maleate + felodipine) |
Category: | Angiotensin-converting Enzyme Inhibitors, Antihypertensive Agents |
CAS number: | 75847-73-3 |
Indication: | For the treatment of essential or renovascular hypertension and symptomatic congestive heart failure. It may be used alone or in combination with thiazide diuretics. |
---|---|
Pharmacology: |
Enalapril is a prodrug that is rapidly metabolized by liver esterases to enalaprilat following oral administration. Enalapril itself has little pharmacologic activity. Enalaprilat lowers blood pressure by antagonizing the effect of the RAAS. The RAAS is a homeostatic mechanism for regulating hemodynamics, water and electrolyte balance. During sympa...
show more » |
Mechanism of Action: |
There are two isoforms of ACE: the somatic isoform, which exists as a glycoprotein comprised of a single polypeptide chain of 1277; and the testicular isoform, which has a lower molecular mass and is thought to play a role in sperm maturation and binding of sperm to the oviduct epithelium. Somatic ACE has two functionally active domains, N and C, w...
show more » |
Absorption: | 55-75%, absorption is unaffected by food; enalaprilat (clinically administered IV) is poorly absorbed, 3-12%, due to its high polarity. |
Protein binding: | 50-60% of enalaprilat is bound to plasma proteins |
Biotransformation: | ~ 60% of absorbed dose is extensively hydrolyzed to enalaprilat, primarily by liver esterases |
Route of elimination: | Excretion of enalapril is primarily renal. |
Half Life: | < 2 hours for unchanged enalapril in health individuals, may be increased in those with congestive heart failure (3.4 and 5.8 hours for single 5- and 10-mg doses, respectively). The average terminal half life of enalaprilat is 35-38 hours. The effective half life following multiple doses is 11-14 hours. |
Toxicity: | Overdosage may result in marked hypotension and stupor. Most common adverse effects include hypotension, headache, dizziness and fatigue. |
Affected organisms: | Humans and other mammals |
Food interaction: |
| ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Drug interaction: |
|